Immunogenicity of Live Attenuated B. pertussis BPZE1 Producing the Universal Influenza Vaccine Candidate M2e

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Kammoun, Hana ^a,b   Roux, Xavier ^a,b,e   Raze, Dominique ^a,b   Debrie, Anne Sophie ^a,b   de Filette, Marina ^c,d   Ysenbaert, Tine ^c,d   Mielcarek, Nathalie ^a,b   Saelens, Xavier ^c,d   Fiers, Walter ^c,d   Locht, Camille ^a,b  

^a INSERM U1019   (France)

^b UNIV LILLE   (France)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d GHENT UNIVERSITY   (Belgium)

^e Bâtiment le Forum 2 Archamps Technopô le   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; LIVE VACCINE; M2E PROTEIN; MATRIX PROTEIN; PERTUSSIS VACCINE; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; GENE FUSION; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS A; MORTALITY; MOUSE; NONHUMAN; PERTUSSIS; RESPIRATORY TRACT INFECTION; VACCINATION; VIRUS IMMUNITY; VIRUS LIKE AGENT; VIRUS LOAD;

ADHESINS, BACTERIAL; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; BORDETELLA PERTUSSIS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; RESPIRATORY SYSTEM; SURVIVAL ANALYSIS; VACCINATION; VACCINES, SYNTHETIC; VIRAL MATRIX PROTEINS; VIRULENCE FACTORS, BORDETELLA;

EID: 84875121302     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059198     Document Type: Article

References (50)

1. Fauci AS, Morens DM, (2012) The perpetual challenge of infectious diseases. N Engl J Med 366: 454-461.
2. Holmgren J, Svennerholm AM, (2012) Vaccines against mucosal infections. Curr Opin Immunol 24: 343-353.
3. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, et al. (2004) Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 350: 896-903.
4. Rose MA, Zielen S, Baumann U, (2012) Mucosal immunity and nasal influenza vaccination. Expert Rev Vaccines 11: 595-607.
5. Mielcarek N, Debrie AS, Raze D, Bertout J, Rouanet C, et al. (2006) Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog 2: e65.
6. Skerry CM, Cassidy JP, English K, Feunou-Feunou P, Locht C, et al. (2009) A live attenuated Bordetella pertussis candidate vaccine does not cause disseminating infection in gamma interferon receptor knockout mice. Clin Vaccine Immunol 16: 1344-1351.
7. Feunou PF, Kammoun H, Debrie AS, Mielcarek N, Locht C, (2010) Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1. Vaccine 28: 7047-7053.
8. Feunou PF, Ismaili J, Debrie AS, Huot L, Hot D, et al. (2008) Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1. Vaccine 26: 5722-5727.
9. Kavanagh H, Noone C, Cahill E, English K, Locht C, et al. (2010) Attenuated Bordetella pertussis vaccine strain BPZE1 modulates allergen-induced immunity and prevents allergic pulmonary pathology in a murine model. Clin Exp Allergy 40: 933-941.
10. Li R, Cheng C, Chong SZ, Lim ARF, Goh YF, et al. (2012) Attenuated Bordetella pertussis BPZE1 protects against allergic airway inflammation and contact dermatitis in mouse models. Allergy 67: 1250-1258.
11. Li R, Lim A, Phoon MC, Narasaraju T, Ng JK, et al. (2010) Attenuated Bordetella pertussis protects against highly pathogenic influenza A viruses by dampening the cytokine storm. J Virol 84: 7105-7113.
12. Mielcarek N, Riveau G, Remoue F, Antoine R, Capron A, et al. (1998) Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis. Nat Biotechnol 16: 454-457.
13. Coppens I, Alonso S, Antoine R, Jacob-Dubuisson F, Renauld-Mongenie G, et al. (2001) Production of Neisseria meningitidis transferrin-binding protein B by recombinant Bordetella pertussis. Infect Immun 69: 5440-5446.
14. Reveneau N, Alonso S, Jacob-Dubuisson F, Mercenier A, Locht C, (2001) Tetanus toxin fragment C-specific priming by intranasal infection with recombinant Bordetella pertussis. Vaccine 20: 926-933.
15. Alonso S, Willery E, Renauld-Mongenie G, Locht C, (2005) Production of nontypeable Haemophilus influenzae HtrA by recombinant Bordetella pertussis with the use of filamentous hemagglutinin as a carrier. Infect Immun 73: 4295-4301.
16. Ho SY, Chua SQ, Foo DG, Locht C, Chow VT, et al. (2008) Highly attenuated Bordetella pertussis strain BPZE1 as a potential live vehicle for delivery of heterologous vaccine candidates. Infect Immun 76: 111-119.
17. Li R, Lim A, Ow ST, Phoon MC, Locht C, et al. (2011) Development of live attenuated Bordetella pertussis strains expressing the universal influenza vaccine candidate M2e. Vaccine 29: 5502-5511.
18. Fiers W, De Filette M, Birkett A, Neirynck S, Min Jou W, (2004) A "universal" human influenza A vaccine. Virus Res 103: 173-176.
19. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, et al. (1999) A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5: 1157-1163.
20. De Filette M, Min Jou W, Birkett A, Lyons K, Schultz B, et al. (2005) Universal influenza A vaccine: optimization of M2-based constructs. Virology 337: 149-161.
21. Schotsaert M, De Filette M, Fiers W, Saelens X, (2009) Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 8: 499-508.
22. Renauld-Mongenie G, Cornette J, Mielcarek N, Menozzi FD, Locht C, (1996) Distinct roles of the N-terminal and C-terminal precursor domains in the biogenesis of the Bordetella pertussis filamentous hemagglutinin. J Bacteriol 178: 1053-1060.
23. Guédin S, Willery E, Locht C, Jacob-Dubuisson F, (1998) Evidence that a globular conformation is not compatible with FhaC-mediated secretion of the Bordetella pertussis filamentous haemagglutinin. Mol Microbiol 29: 763-774.
24. Antoine R, Alonso S, Raze D, Coutte L, Lesjean S, et al. (2000) New virulence-activated and virulence-repressed genes identified by systematic gene inactivation and generation of transcriptional fusions in Bordetella pertussis. J Bacteriol 182: 5902-5905.
25. Relman DA, Domenighini M, Tuomanen E, Rappuoli R, Falkow S, (1989) Filamentous hemagglutinin of Bordetella pertussis: nucleotide sequence and crucial role in adherence. Proc Natl Acad Sci U S A 86: 2637-2641.
26. Kimura A, Mountzouros KT, Relman DA, Falkow S, Cowell JL, (1990) Bordetella pertussis filamentous hemagglutinin: evaluation as a protective antigen and colonization factor in a mouse respiratory infection model. Infect Immun 58: 7-16.
27. Alonso S, Reveneau N, Pethe K, Locht C, (2002) Eighty-kilodalton N-terminal moiety of Bordetella pertussis filamentous hemagglutinin: adherence, immunogenicity, and protective role. Infect Immun 70: 4142-4147.
28. Alonso S, Pethe K, Mielcarek N, Raze D, Locht C, (2001) Role of ADP-ribosyltransferase activity of pertussis toxin in toxin-adhesin redundancy with filamentous hemagglutinin during Bordetella pertussis infection. Infect Immun 69: 6038-6043.
29. Mielcarek N, Debrie AS, Mahieux S, Locht C, (2010) Doser response of attenuated Bordetella pertussis BPZE1-induced protection in mice. Clin Vaccine Immunol 17: 317-324.
30. Beigel JH, (2008) Influenza. Crit Care Med 36: 2660-2666.
31. Aoki FY, Macleod MD, Paggiaro P, Garewicz O, El Sawy A, et al. (2003) Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 51: 123-129.
32. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, et al. (2004) Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364: 759-765.
33. Kilbourne ED, (1978) Influenza as a problem in immunology. J Immunol 120: 1447-1452.
34. Jefferson T, Rivetti D, Di Pietrantonj C, Rivetti A, Demicheli V (2007) Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2(CD001269).
35. Cox RJ, Brokstad KA, Ogra P, (2004) Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 59: 1-15.
36. De Filette M, Fiers W, Martens W, Birkett A, Ramne A, et al. (2006) Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 24: 6597-6601.
37. McGuirk P, McCann C, Mills KH, (2002) Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J Exp Med 195: 221-231.
38. Menozzi FD, Boucher PE, Riveau G, Gantiez C, Locht C, (1994) Surface-associated filamentous hemagglutinin induces autoagglutination of Bordetella pertussis. Infect Immun 62: 4261-4269.
39. Wammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, et al. (2011) Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 208: 181-193.
40. Weinfurter JT, Brunner K, Capuano SV, Chengung L, Broman KW, et al. (2011) Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates. PLoS Pathog 7: e1002381.
41. Atsmon J, Kate-Ilovitz E, Shaikevich D, Singer Y, Volokhov I, et al. (2012) Safety and immunogenicity of multimeric-001- a novel universal influenza vaccine. J Clin Immunol 32: 595-603.
42. Adar Y, Singer Y, Levi R, Tzehoval E, Perk S, et al. (2009) A universal epitope-based influenza vaccine and its efficacy against H5N1. Vaccine 27: 2099-2107.
43. Menozzi FD, Mutombo R, Renauld G, Gantiez C, Hannah JH, et al. (1994) Heparin-inhibitable lectin activity of the filamentous hemagglutinin adhesin of Bordetella pertussis. Infect Immun 62: 769-778.
44. Stainer DW, Scholte MJ, (1970) A simple chemically defined medium for the production of phase I Bordetella pertussis. J Gen Microbiol 63: 211-220.
45. Quandt J, Hynes MF, (1993) Versatile suicide vectors which allow direct selection for gene replacement in gram-negative bacteria. Gene 127: 15-21.
46. Simon R, Priefer U, Pühler A, (1983) A broad host range mobilization system for in vivo genetic engineering: transposon mutagenesis in Gram-negative bacteria. Bio/technology I: 784-791.
47. Stibitz R, (1994) Use of conditionally counterselectable suicide vectors for allelic exchange. Methods Enzymol 235: 458-465.
48. Laemmli UK, (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
49. Reed LJ, Muench H, (1938) A simple method of estimating fifty per cent endpoints. Am J Epidemiol 27: 493-497.
50. Locht C, Geoffroy MC, Renauld G, (1992) Common accessory genes for the Bordetella pertussis filamentous hemagglutinin and fimbriae share sequence similarities with the papC and papD gene families. EMBO J 11: 3175-3183.